Edition:
India

People: Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

75.00USD
1:30am IST
Change (% chg)

$0.79 (+1.06%)
Prev Close
$74.21
Open
$74.47
Day's High
$75.19
Day's Low
$72.76
Volume
400,343
Avg. Vol
437,448
52-wk High
$106.69
52-wk Low
$70.90

Bienaime, Jean-Jacques 

Mr. Jean-Jacques Bienaime serves as Chairman of the Board, Chief Executive Officer of Biomarin Pharmaceutical Inc., He joined our Board in May 2005, the same time that he became our Chief Executive Officer, and was named Chair of the Board in June 2015. From November 2002 to April 2005, Mr. Bienaimé served as Chairman, Chief Executive Officer, and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. From 1998 to late 2002, Mr. Bienaimé served as Chairman, Chief Executive Officer and President of Sangstat Medical Corporation, an immunology-focused biotechnology company, becoming President in 1998 and Chief Executive Officer in 1999. From 1992 to 1998, Mr. Bienaimé held several senior management positions at Rhône-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis), culminating in the position of Senior Vice President of Worldwide Marketing and Business Development. Earlier in his career, Mr. Bienaimé worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks. Mr. Bienaimé currently serves on the boards of Incyte Corporation and Vital Therapies, Inc., both public biotechnology companies, as well as the Health Section Governing Board of The Biotechnology Innovation Organization (formerly known as The Biotechnology Industry Organization), an industry trade association, and in January 2018 he joined the board of PhRMA, an industry trade organization. Mr. Bienaimé previously served on the boards of two public companies: Portola Pharmaceuticals, Inc., from 2011 to 2014, and InterMune, Inc., from 2012 to 2014. Mr. Bienaimé received an M.B.A. from the Wharton School at the University of Pennsylvania and a degree in economics from the École Supérieure de Commerce de Paris.

Basic Compensation

Total Annual Compensation, USD 1,094,420
Restricted Stock Award, USD 7,783,880
Long-Term Incentive Plans, USD --
All Other, USD 7,038,690
Fiscal Year Total, USD 15,917,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable 487,500 1,553,500.00
Exercised 132,423 9,243,880.00
Name Fiscal Year Total

Jean-Jacques Bienaime

15,917,000

Daniel Spiegelman

4,641,880

Henry Fuchs

7,045,420

G. Eric Davis

2,708,210

Jeff Ajer

4,568,300

Robert Baffi

4,473,230
As Of  31 Dec 2017